bluuebunny/crossref_metadata_2025_split huggingface dataset:
SACUBITRIL/VALSARTAN ON CLINICAL, LABORATORY, AND ECHOCARDIOGRAPHIC VARIABLES IN HONDURANS WITH HEART FAILURE WITH REDUCED LEFT VENTRICULAR EJECTION FRACTION. FIVE YEARS EXPERIENCE
Authors: Alvarenga Francisco Somoza , Martinez Juan Fernando Toledo , Cano Jose Francisco Somoza , Handal Ramses Amaya 
Published: June 2023

Objective:
This study aimed to describe the response to sacubitril/valsartan in a group of Hondurans with heart failure and reduced Left Ventricular Ejection Fraction (LVEF) between January 2018 and December 2022.

Design and method:
This observational, descriptive, retrospective cohort study was conducted on 216 adult patients with heart failure and reduced Left Ventricular Ejection Fraction (LVEF) who received treatment with angiotensin-receptor antagonist/neprilysin inhibitors (sacubitril/valsartan) in two medical center in Honduras. The study participants included the patients with LVEF < 40% treated with sacubitril/valsartan for at least one year. The patients also received optimal medical therapy for HFrEF according to the American Heart Association -guidelines.

Results:
This study was conducted on 216 patients with HFrEF treated with SAC/VAL. The median age of the patients was 71 years. The sociodemographic and clinical variables have been presented in Table 1.
Treatment with SAC/VAL was done at three dosages (24/26 mg, 49/51 mg, and 97/103 mg) twice a day. For most of the patients, the treatment was started with 24/26 mg and the dose was progressively titrated to the maximum tolerated dose. 60% completed the follow-up at the optimal dose of 97/103 mg.
All the patients had at least one underlying comorbidity. The main comorbidity was hypertension (92.4%) followed by dyslipidemia (61.9%)
At the beginning of the study, 64.8%, 29.5% and 5.7% of the patients were in NYHA functional classes IV, III, and II, respectively. Following six months of treatment with SAC/VAL, 58.1% of the patients were in the functional class II, 28.6% were in class III, 9.5% were in class IV and 3.8% were in class I. Based on the results, 82.9% of the patients (n = 180) presented improvement, 16.2% (n = 34) had unchanged functional classes, and 1% showed worse baseline conditions (Figure 1).
The results revealed the improvement of LVEF in 94.3% of the cases after treatment with SAC/VAL, while 3.8% presented no changes in this regard.

Conclusions:
The study population had sociodemographic and clinical similarities with the Latin American Cohort in the PARADIGM-HF trial with the significant improvement of the LVEF and functional class.
CIRCULATING BIOACTIVES RESULTING FROM TOTUM-854 ABSORPTION IN HUMANS PROTECTS PRIMARY HUMAN ENDOTHELIAL CELLS AGAINST LIPOTOXICITY: LESSONS FROM AN ORIGINAL EX VIVO CLINICAL TRIAL
Authors: Wauquier Fabien , Ripoche Doriane , Boutin-Wittrant Line , Otero Yolanda F. , Joubioux Florian Le , Maugard Thierry , Roux Veronique , Macian Nicolas , Pickering Gisele , Bargetto Maxime , Sapone Veronique , Cazaubiel Murielle , Peltier Sebastien , Sirvent Pascal , Wittrant Yohann 
Published: June 2023

Objective:
TOTUM-854 is a patented plant blend extract characterized for its polyphenol-rich content that supports hypertension prevention in preclinical studies. However, clinically validated approaches and further investigations on the mode of action at the cellular level especially in humans are required for optimized care management. In this study, we designed an ex-vivo clinical innovative approach considering the circulating metabolites produced by the digestive tract following the ingestion of TOTUM-854 in humans.

Design and method:
Human serum was collected in healthy subjects before and following acute intake of 3.71g of TOTUM-854. Availability of circulating metabolites was confirmed and characterized by UPLC-MS. Human serum enriched with metabolites deriving from TOTUM-854 absorption was further incubated with human endothelial cells (HUVEC), pretreated or not with palmitate (200 μM). In such lipotoxic environment, HUVEC behavior was monitored to determine whether and how TOTUM-854 metabolites may improve vascular response in humans.

Results:
In the presence of the human metabolites from TOTUM-854, HUVECs were protected from an induced lipotoxic stress. No effect on cell toxicity was detected in the presence of enriched sera. HUVEC protection was characterized by (1) decreased ACE-1 activity (-32% p<0.0001); (2) the inhibition of oxidative stress with decreased ROS (-12% observed by DCFDA, and by DHE fluorescent microscopy) as well as decreased Nox2 gene expression (-6,7 fold change vs palmitate, p<0.01); (3) the inhibition of inflammatory response, with a decrease in IL-1↓ release (-37% compared to palmitate, p<0.001) and decreased MCP-1 et VCAM-1 gene expression (-93% p<0.001 and -77% p<0.001 respectively). All together, these data provide new biochemical mechanisms for a protective role of TOTUM-854 in human endothelial cells.

Conclusions:
Using a pioneering clinical ex vivo approach considering the circulating and bioavailable actives, we give clues on the role of metabolites produced following TOTUM-854 intake in humans in vascular protection.
ACUPUNCTURE IN ARTERIAL HYPERTENSION: EVALUATION OF ITS EFFICACY WITH BOTH OFFICE AND AMBULATORY BLOOD PRESSURE MEASUREMENTS
Authors: Migliarese Cristina , Maloberti Alessandro , Gatto Roberto , Algeri Michela , Gualini Elena , Biolcati Marco , Ruzzenenti Giacomo , Giannattasio Cristina 
Published: June 2023

Objective:
A possible alternative to pharmacological antihypertensive therapies in grade 1 low risk hypertensive patients or in those experienced drugs adverse effects could be acupuncture.

Design and method:
We focused on its possible effects on BP both as Office BP (OBP) and as Ambulatory BP Monitoring (ABPM) evaluating it before starting a 6 weeks twice weekly (total 12 session) acupuncture cycle and after 2 months from its completion.
In this prospective study we treated with acupuncture 45 patients: 24 of them presents high-normal BP values and low cardiovascular risk while 21 patients were on anti-hypertensive drug with slightly uncontrolled BP values (from 140 to 145 mmHg for Systolic BP – SBP – and/or from 90 to 95 mmHg for Diastolic BP – DBP).

Results:
Regarding SBP, a significant reduction have been observed for office values (from 134.2±15.7 to 125.1±12.2, p = 0.03), and for ABPM 24h (from 131.1±10.7 to 126.0±10.1, p = 0.01) and day-time values (from 134.7±10.5 to 127.1±18.4, p = 0.02). For DBP, only ABPM 24h and day-time values showed significant changes (from 85.3±9.1 to 82.1±7.5, p = 0.03; and from 88.5±9.3 to 85.7±7.8, p = 0.02). Within session SBP decrease was -5.8 mmHg (-3.75%) during the first session while it falls to -2.1 mmHg (-1.25%) and stands firmly under 2 mmHg for all the next session. At the last session SBP reduction was -1.9 mmHg (-1.6%).

Conclusions:
We found a significant reduction in office, 24h and day-time ABPM SBP determined by a 6-weeks twice weekly acupuncture cycle that lasts at least for the first two months after its completion.
PSYCHIATRIC SEQUELAE OF CALCIUM CHANNEL BLOCKERS – PRELIMINARY RESULTS FROM A SYSTEMATIC REVIEW AND META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS
Authors: Fürtig Marc-Alexander , Kovalenko Yana , Kreutz Reinhold , Riemer Thomas Günther 
Published: June 2023

Objective:
L-type Calcium Channel Blockers (CCB) are widely used in the treatment of hypertension and other cardiovascular diseases. The risk of adverse events such as hypotension and edema for dihydropyridine-CCB (DHP), and bradycardia, atrioventricular block, and constipation for non-dihydropyridine-CCB (non-DHP) is well known. In addition, CCB have also been suspected of causing psychiatric adverse events (PAE). In our study, we evaluate the risk of PAE during CCB therapy.

Design and method:
We conducted a systematic search in literature databases and clinical trial registries to identify placebo-controlled randomized controlled trials (RCT) that reported frequencies of PAE during CCB therapy. We extracted data on frequencies of PAE and reviewed them, taking into account the total number of exposed patients. We separately calculated odds ratios (OR) with a 95% confidence interval (CI) for PAE in users of DHP or non-DHP CCB.

Results:
We retrieved 86 eligible placebo-controlled studies, encompassing 14,585 patients exposed to CCB. Main indications for CCB use were hypertension (64 studies) and angina pectoris (11 studies). PAE were reported in 1,425 patients, with fatigue, depression, agitation, and insomnia accounting for most of cases (299, 272, 113, and 105 respectively). Meta-analyses were possible for eight symptoms in DHP studies and for two symptoms in non-DHP studies, with a total of 73 RCT contributing data. We found no significant differences between the risk of PAE during DHP (anxiety (OR = 0.85; CI = 0.47–1.54; p = 0.58), depression (OR = 0.87; CI = 0.73–1.03; p = 0.11), unusual dreams (OR = 0.92; CI = 0.47–1.80; p = 0.80), fatigue (OR = 1.15; CI = 0.91–1.46; p = 0.24), insomnia (OR = 0.90; CI = 0.62–1.29; p = 0.55), nervousness (OR = 1.18; CI = 0.87–1.59; p = 0.29), sleep disorders (OR = 1.26; CI = 0.68–2.33; p = 0.47), and somnolence (OR = 1.15; CI = 0.77–1.71; p = 0.49) or non-DHP (fatigue (OR = 1.32; CI = 0.76–2.27; p = 0.32) and insomnia (OR = 0.94; CI = 0.31–2.86; p = 0.92)) compared to placebo.

Conclusions:
PAE are occasionally reported during CCB therapy but not more frequently than during placebo. Therefore, CCB do not impose a risk of psychiatric sequelae and can be considered safe regarding mental health.
LOSARTAN/AMLODIPINE IN ARTERIAL STIFFNESS SHOWS DOMINANT EFFICACY IN REDUCING 24 HOURS BRACHIAL AND CENTRAL BP COMPARED WITH LOSARTAN/HYDROCHLOROTHIAZID OR IN NORMAL ARTERY
Authors: Cho Eun Joo , Lee Hae Young , Sung Ki Chul , Park Sungha , Sohn Il-Suk , Park Chang Gyu , Choi Dong-Ju , Ha Jong Won , Ahn Young Keun , Shin Jinho , Hong Soon-Jun , Kim Soon Kil , Chung Wook-Jin , Yoo Byung Su , Hong Taek Jong , Youn Ho Joong , Cho Myeong-Chan , Chae Shung Chull , Kim Young Jo , Kim Chong-Jin 
Published: June 2023

Objective:
The aim of this research was to compare the efficacy between 20 weeks treatments of losartan/amlodipine(L/A) versus losartan/hydrochlorothiazide(L/H) combination therapy in reducing 24 hours brachial and central blood pressure (BP) according to the severity of baseline arterial stiffness measured by 24 hours pulse wave velocity (PWV).

Design and method:
The K-central research was a prospective, randomized, double-blind, multicenter trial including 231 hypertensive patients (mean age = 59.2±12.2 years). Patients take losartan 50 mg monotherapy for 4 weeks, followed by additional amlodipine 5 mg (L/A) or hydrochlorothiazide 12.5 mg (L/H) for 20 weeks after randomization. The patients who did not achieve the BP goal after 4 weeks’ randomization receive an increased dose of losartan 100 mg for the L/A group and increased doses of losartan 100 mg and hydrochlorothiazide 25 mg for L/H group. The 24 hours brachial BP, central BP, and PWV were measured using an oscillometric device (Mobil-O-Graph 24-hour PWA monitor, I.E.M. Gmbh, Stolberg, Germany) at baseline and after 20 weeks’ treatment.

Results:
The main results of this research are presented in the table and figure.

Conclusions:
We concluded that L/A combination therapy in subjects with advanced arterial stiffness shows dominant efficacy in reducing 24 hours mean brachial and central BP compared with in subjects without arterial stiffness or with L/H combination therapy.
Positive Predictive Values and Outcomes for Uninformative Cell-Free DNA Tests: An Italian Multicentric Cytogenetic and Cytogenomic Audit of DiagnOstic Testing (ICARO Study)
Authors: Grati Francesca Romana , Bestetti Ilaria , de Siero Daria , Malvestiti Francesca , Villa Nicoletta , Sala Elena , Crosti Francesca , Parisi Valentina , Nardone Anna Maria , Di Giacomo Gianluca , Pettinari Antonella , Tortora Giada , Montaldi Annamaria , Calò Annapaola , Saccilotto Donatella , Zanchetti Sara , Celli Paola , Guerneri Silvana , Silipigni Rosamaria , Cardarelli Laura , Lippi Elisabetta , Cavani Simona , Malacarne Michela , Genesio Rita , Beltrami Nicola , Pittalis Maria Carla , Desiderio Laura , Gentile Mattia , Ficarella Romina , Recalcati Maria Paola , Catusi Ilaria , Garzo Maria , Miele Lorena , Corti Cecilia , Ghezzo Sara , Bertini Veronica , Cambi Francesca , Valetto Angelo , Facchinetti Barbara , Bernardini Laura , Capalbo Anna , Balducci Federica , Pelo Elisabetta , Minuti Barbara , Pescucci Chiara , Giuliani Costanza , Renieri Alessandra , Longo Ilaria , Tita Rossella , Castello Giuseppe , Casalone Rosario , Righi Rossana , Raso Barbara , Civolani Alessandro , Muzi Maria Cristina , di Natale Manuela , Varriale Luigia , Gasperini Daniela , Nuzzi Maria Cristina , Cellamare Angelo , Casieri Paola , Busuito Rosa , Ceccarini Caterina , Cesarano Carla , Privitera Orsola , Melani Daniela , Menozzi Cristina , Falcinelli Cristina , Calabrese Olga , Battaglia Paola , Tanzariello Antonella , Stampalija Tamara , Ardisia Carmela , Gasparini Paolo , Benn Peter , Novelli Antonio 
Published: June 2023

(Abstracted from Prenat Diagn 2022;42:1575–1586
Methods for diagnosis of genetic abnormalities have recently undergone substantial improvement. Noninvasive prenatal testing (NIPT) is performed early in pregnancy, typically at the end of the first trimester using cell-free DNA (cfDNA) to identify 3 commonly occurring trisomies (13, 18, and 21).
The Impact of Paternal Age on New Mutations and Disease in the Next Generation
Authors: Wood Katherine A. , Goriely Anne 
Published: June 2023

(Abstracted from Fertil Steril 2022;118(6):1001–1012
Previous research has long established a link between genetic disorders and advanced maternal age. Newer research has shown an additional and independent link between advanced paternal age and difficulty conceiving, complications during pregnancy, and increased possibility of many conditions including spontaneous dominant disorders, congenital abnormalities, neurodevelopmental conditions, and malignancies.
Outcomes of a Career Development Award (Pre-K) Mock Review Program for Postdoctoral Fellows and Early-Career Faculty
Authors: Castillo-Mancilla Jose R. , Erlandson Kristine M. , Hecker Emily R. , Komaie Goldie , Shomaker Lauren B. , Cicutto Lisa , Mankin Galit , Maclean Paul 
Published: June 2023

Purpose
Securing research funding for early-career investigators remains challenging. The authors present the results of a presubmission career development award (Pre-K) review program for postdoctoral fellows and early-career faculty.

Method
The Pre-K program is designed to help mentored postdoctoral fellows and early-career faculty write successful career development awards by assigning expert reviewers to score each application and provide written and oral critiques before a mock study section. Applicants and mentors attend the review and can ask questions directly to reviewers about their application. Quarterly, annual, and alumni surveys are sent to applicants who participated in the Pre-K program to assess satisfaction, confirm grant submission and status (i.e., funded and unfunded), and understand the long-term career impact of the program.

Results
A total of 212 applicants (136 [64%] female; 19 [9%] from underrepresented in medicine groups) participated in the program between 2014 and 2021. Outcome data from 194 grants were available. Among these grants, 71 were awarded (37% success rate). Among underrepresented in medicine applicants, 7 of 18 submitted grants were funded (39% success rate). Of 183 Pre-K participants sent the alumni survey, 123 (67%) responded. Academic degrees included 64 PhDs (52%), 46 MDs (37%), and 14 MDs/PhDs (11%). One hundred nine respondents (90%) were employed in an academic institution, and 106 (86%) devoted more than 50% of their time to research. One hundred twelve (91%) reported receipt of an award (87 [78%] federal and 59 [53%] intramural funding), the most common being National Institutes of Health K/Career Development Awards. Pre-K was rated as very useful to their careers by 102 respondents (83%).

Conclusions
A Pre-K mock review program can assist early-career investigators in securing funding and launching their research career. Continued investment in the next generation of clinical and translational researchers should remain an institutional priority.
All-cause mortality in moderate and severe COVID-19 patients with myocardial injury receiving versus not receiving azvudine: a propensity score-matched analysis
Authors: Chen Ru , Guo Yi , Deng Shan , Wang Jian , Gao Meng , Han Hongli , Wang Lin , Jiang Hongwei , Huang Kai 
Published: June 2023

Background and purpose:
Omicron is currently the dominant strain of severe acute respiratory syndrome coronavirus 2, but little is known about the characteristics and management of omicron related myocardial injury, particularly the potential benefit of the antiviral agent azvudine.

Methods:
Patients with confirmed and suspected coronavirus disease 2019 (COVID-19) admitted to Wuhan Union Hospital from December 7, 2022, to December 30, 2022, were included in this study. Cox regression was conducted to identify risk factors for all-cause mortality. A propensity score-matched analysis was performed at a 1:1 ratio with a caliper of 0.1 pooled standard deviations of relevant confounders.

Results:
The final analysis included a total of 332 patients (167 confirmed cases and 165 suspected cases), 42.77% (142/332) of the patients aged over 80 years and 68.67% (228/332) of them were men, 158 of the patients were treated with azvudine. In the matched cohort, a total of 60 (30.30%, 60/198) patients deceased, 40 (20.20%, 40/198) of the patients received noninvasive ventilation and 22 (11.11%, 22/198) received invasive ventilation, 34 (17.17%, 34/198) of the cases were admitted to intensive care unit (ICU). The rate of shock, multiple organ damages and arrhythmia were 11.62% (23/198), 20.20% (40/198), and 12.12% (24/198), respectively. There was no significant difference on these clinical outcomes in patients treated with azvudine or not. Azvudine reduced early mortality (within 14 days from admission) (hazard ratio: 0.37, 95% confidence interval: 0.18–0.77) even after adjusting for other treatments including glucocorticoids, immunoglobin and anticoagulant therapy, but not the final in-hospital mortality of patients.

Conclusions:
Patients with COVID-19-related myocardial injury had a high mortality of about 30.30% (60/198). Azvudine improved the early survival of the patients but not final mortality.
Comprehensive quantitative sensory testing shows altered sensory function in women with chronic pelvic pain: results from the Translational Research in Pelvic Pain (TRiPP) Study
Authors: Coxon Lydia , Vollert Jan , Perro Danielle , Lunde Claire E. , Ferreira-Gomes Joana , Charrua Ana , Abreu-Mendes Pedro , Krassowski Michal , Birch Judy , Meijlink Jane , Hummelshoj Lone , Hoffmann Anja , Aziz Qasim , Arendt-Nielsen Lars , Pogatzki-Zahn Esther , Evans Emma , Demetriou Lysia , McMahon Stephen B. , Missmer Stacey A. , Becker Christian M. , Zondervan Krina T. , Horne Andrew W. , Cruz Francisco , Sieberg Christine B. , Treede Rolf-Detlef , Nagel Jens , Vincent Katy 
Published: June 2023

Abstract
Chronic pelvic pain (CPP), despite its high prevalence, is still relatively poorly understood mechanistically. This study, as part of the Translational Research in Pelvic Pain (TRiPP) project, has used a full quantitative sensory testing (QST) paradigm to profile n = 85 women with and without CPP (endometriosis or bladder pain specifically). We used the foot as a control site and abdomen as the test site. Across 5 diagnostically determined subgroups, we found features which are common across different aetiologies, eg, gain of function in pressure pain threshold (PPT) when assessing responses from the lower abdomen or pelvis (referred pain site). However, disease-specific phenotypes were also identified, eg, greater mechanical allodynia in endometriosis, despite there being large heterogeneities within diagnostic groups. The most common QST sensory phenotype was mechanical hyperalgesia (>50% across all the groups). A “healthy’ sensory phenotype was seen in <7% of CPP participants. Specific QST measures correlated with sensory symptoms assessed by the painDETECT questionnaire (pressure-evoked pain [painDETECT] and PPT [QST] [r = 0.47, P < 0.001]; mechanical hyperalgesia (painDETECT) and mechanical pain sensitivity [MPS from QST] [r = 0.38, P = 0.009]). The data suggest that participants with CPP are sensitive to both deep tissue and cutaneous inputs, suggesting that central mechanisms may be important in this cohort. We also see phenotypes such as thermal hyperalgesia, which may be the result of peripheral mechanisms, such as irritable nociceptors. This highlights the importance of stratifying patients into clinically meaningful phenotypes, which may have implications for the development of better therapeutic strategies for CPP.
Pelvic Girdle Pain in Pregnancy: A Review
Authors: Sward Lindsey , Manning Nirvana , Murchison Amanda B. , Ghahremani Taylor , McCaulley Jill A. , Magann Everett F. 
Published: June 2023

Importance
Pelvic girdle pain is often thought to be a recent phenomenon, but this condition was described as early as 400 BC by Hippocrates. Despite being identified for years, confusion continues about the definition and management of this ailment affecting many pregnancies.

Objectives
The purpose of the review is to assess the incidence, etiology, pathophysiology, risk factors, diagnosis, management, and pregnancy outcomes/recovery of current pregnancies, and outcomes of future pregnancies complicated by pelvic girdle pain.

Evidence Acquisition
Electronic databases (PubMed and Embase) were searched from 1980 to 2021 with the only limitation being that the articles were in English. Studies were selected that examined associations between pelvic pain/pelvic girdle pain and pregnancy.

Results
There were 343 articles identified. After reviewing the abstracts, 88 were used in this review. Pelvic girdle pain is a common condition of pregnancy, affecting a reported 20% of pregnant women. The pathophysiology is poorly understood and likely multifactorial, involving both hormonal and biomechanical changes that occur during pregnancy. Several risk factors have been identified. This diagnosis is most commonly made based on symptoms related to pelvic pain during pregnancy. Treatment should be multimodal, including pelvic girdle support, stabilizing exercises, analgesia, and potentially complementary therapies. The effects on future pregnancies are uncertain, although some limited information suggests an increased risk of recurrent PGP in subsequent pregnancies.

Conclusions
Pelvic girdle pain in pregnancy is a common condition that is often overlooked as a normal part of pregnancy but has a significant impact on quality of life during, after, and in subsequent pregnancies. Multimodal therapies are available and are largely low cost and noninvasive.

Relevance
Our aim is to increase the awareness of pelvic girdle pain in pregnancy as a common but often underdiagnosed and undertreated condition.

Target Audience
Obstetricians and gynecologist, family physicians.

Learning Objectives
After completing this activity, the learner should be better able to describe the diagnosis, etiology, and pathophysiology of pelvic girdle pain; identify risk factors and appropriate management; and predict reoccurrence in a subsequent pregnancy.
Pharmacologic Interventions to Minimize Fluid Absorption at the Time of Hysteroscopy: A Systematic Review and Meta-analysis
Authors: Désilets Jade , Zakhari Andrew , Chagnon Miguel , Ekmekjian Taline , Nguyen Dong Bach , Smith Jessica Papillon , Mansour Fady W. , Krishnamurthy Srinivasan 
Published: June 2023

(Abstracted from Obstet Gynecol 2023;141:285–298
With a range of both therapeutic and diagnostic indications, hysteroscopy is one of the gynecological procedures most commonly performed. Although both effective and generally safe, this intervention does carry a small risk of fluid overload, fluid absorption, and electrolyte imbalance (which can on rare occurrence be fatal).